Strategies to improve plasma half life time of peptide and protein drugs
Top Cited Papers
- 20 April 2006
- journal article
- review article
- Published by Springer Science and Business Media LLC in Amino Acids
- Vol. 30 (4), 351-367
- https://doi.org/10.1007/s00726-005-0289-3
Abstract
Due to the obvious advantages of long-acting peptide and protein drugs, strategies to prolong plasma half life time of such compounds are highly on demand. Short plasma half life times are commonly due to fast renal clearance as well as to enzymatic degradation occurring during systemic circulation. Modifications of the peptide/protein can lead to prolonged plasma half life times. By shortening the overall amino acid amount of somatostatin and replacing l-analogue amino acids with d-amino acids, plasma half life time of the derivate octreotide was 1.5 hours in comparison to only few minutes of somatostatin. A PEG2,40 K conjugate of INF-α-2b exhibited a 330-fold prolonged plasma half life time compared to the native protein. It was the aim of this review to provide an overview of possible strategies to prolong plasma half life time such as modification of N- and C-terminus or PEGylation as well as methods to evaluate the effectiveness of drug modifications. Furthermore, fundamental data about most important proteolytic enzymes of human blood, liver and kidney as well as their cleavage specificity and inhibitors for them are provided in order to predict enzymatic cleavage of peptide and protein drugs during systemic circulation.Keywords
This publication has 142 references indexed in Scilit:
- Directed Coevolution of Stability and Catalytic Activity in Calcium-free SubtilisinBiochemistry, 2005
- A non‐amyloidogenic function of BACE‐2 in the secretory pathwayJournal of Neurochemistry, 2002
- A secreted form of human ADAM9 has an α-secretase activity for APPBiochemical and Biophysical Research Communications, 2002
- Susceptibility of ebiratide to proteolysis in rat intestinal fluid and homogenates and its protection by various protease inhibitorsLife Sciences, 1994
- Controlled Release of Thyrotropin Releasing Hormone from Microspheres: Evaluation of Release Profiles and Pharmacokinetics after Subcutaneous AdministrationJournal of Pharmaceutical Sciences, 1994
- Dermorphin analogs: Resistance to in vitro enzymatic degradation is not always increased by additional D-amino acid substitutionsBiochemical and Biophysical Research Communications, 1988
- Prediction of the disposition ofβ-lactam antibiotics in humans from pharmacokinetic parameters in animalsJournal of Pharmacokinetics and Biopharmaceutics, 1984
- Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokineticsJournal of Pharmacokinetics and Biopharmaceutics, 1982
- Sephadex-gel filtration and heat stability of human jejunal and serum pteroylpolyglutamate hydrolase (folate conjugase): Evidence for two different formsBiochemical Medicine, 1975
- Animal scale-upJournal of Pharmacokinetics and Biopharmaceutics, 1973